JP2007504132A5 - - Google Patents

Download PDF

Info

Publication number
JP2007504132A5
JP2007504132A5 JP2006524705A JP2006524705A JP2007504132A5 JP 2007504132 A5 JP2007504132 A5 JP 2007504132A5 JP 2006524705 A JP2006524705 A JP 2006524705A JP 2006524705 A JP2006524705 A JP 2006524705A JP 2007504132 A5 JP2007504132 A5 JP 2007504132A5
Authority
JP
Japan
Prior art keywords
compound
daltons
molecular weight
group
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006524705A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007504132A (ja
JP4848277B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/026422 external-priority patent/WO2005023834A2/en
Publication of JP2007504132A publication Critical patent/JP2007504132A/ja
Publication of JP2007504132A5 publication Critical patent/JP2007504132A5/ja
Application granted granted Critical
Publication of JP4848277B2 publication Critical patent/JP4848277B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2006524705A 2003-08-28 2004-08-13 受容体に結合するペプチドおよび化合物 Expired - Lifetime JP4848277B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49874003P 2003-08-28 2003-08-28
US60/498,740 2003-08-28
PCT/US2004/026422 WO2005023834A2 (en) 2003-08-28 2004-08-13 Peptides and compounds that bind to thrombopoietin receptors

Publications (3)

Publication Number Publication Date
JP2007504132A JP2007504132A (ja) 2007-03-01
JP2007504132A5 true JP2007504132A5 (enExample) 2007-09-20
JP4848277B2 JP4848277B2 (ja) 2011-12-28

Family

ID=34272720

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006524705A Expired - Lifetime JP4848277B2 (ja) 2003-08-28 2004-08-13 受容体に結合するペプチドおよび化合物

Country Status (32)

Country Link
US (1) US7576056B2 (enExample)
EP (1) EP1675606B1 (enExample)
JP (1) JP4848277B2 (enExample)
KR (2) KR101183875B1 (enExample)
CN (2) CN1871022B (enExample)
AR (1) AR045530A1 (enExample)
AU (1) AU2004270656B2 (enExample)
BR (1) BRPI0414008B8 (enExample)
CA (1) CA2537421C (enExample)
CY (1) CY1118965T1 (enExample)
DK (1) DK1675606T3 (enExample)
EA (1) EA009286B1 (enExample)
EC (1) ECSP066396A (enExample)
ES (1) ES2626107T3 (enExample)
HR (1) HRP20170810T1 (enExample)
HU (1) HUE032370T2 (enExample)
IL (1) IL173965A (enExample)
IS (1) IS8300A (enExample)
LT (1) LT1675606T (enExample)
ME (1) ME00313B (enExample)
MX (1) MXPA06002292A (enExample)
NO (1) NO344233B1 (enExample)
NZ (1) NZ545455A (enExample)
PL (1) PL1675606T3 (enExample)
PT (1) PT1675606T (enExample)
RS (2) RS20060141A (enExample)
SG (1) SG131110A1 (enExample)
SI (1) SI1675606T1 (enExample)
TW (1) TWI348375B (enExample)
UA (1) UA82710C2 (enExample)
WO (1) WO2005023834A2 (enExample)
ZA (1) ZA200602495B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091311B2 (en) * 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
MEP42108A (en) 1998-10-23 2011-02-10 Kiren Amgen Inc Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
ES2781475T3 (es) 2002-09-18 2020-09-02 Janssen Pharmaceuticals Inc Métodos para aumentar la producción de células madre hematopoyéticas y plaquetas
US20040149235A1 (en) * 2002-10-04 2004-08-05 Pogue Albert S. Apparatus and method for removal of waste from animal production facilities
US7723295B2 (en) * 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
SG131110A1 (en) 2003-08-28 2007-04-26 Ortho Mcneil Pharm Inc Peptides and compounds that bind to thrombopoietin receptors
US7615533B2 (en) 2004-08-16 2009-11-10 Janssen Pharmaceutica N.V. TPO peptide compounds for treatment of anemia
EP1986677A2 (en) * 2006-01-25 2008-11-05 Amgen Inc. Thrombopoietic compounds
AR059573A1 (es) * 2006-02-14 2008-04-16 Janssen Pharmaceutica Nv Uso de compuestos peptidicos de tpo y composiciones farmaceuticas en el tratamiento de la anemia
DK1984014T3 (da) * 2006-02-14 2014-09-15 Janssen Pharmaceutica Nv Anvendelse af tpo-peptidforbindelser og farmaceutiske sammensætninger ved behandlingen af anæmi
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
ES2729622T3 (es) * 2008-06-03 2019-11-05 Janssen Pharmaceutica Nv Péptido mimético de TPO para prevenir el desorden hematológico asociado al tratamiento contra el cáncer
EP2725053B1 (en) 2011-06-23 2016-02-10 Shimadzu Corporation Branched amphipathic block polymer and molecular aggregate and drug delivery system using same
AU2018306329B8 (en) * 2017-07-26 2025-02-20 Janssen Pharmaceutica Nv Methods of protecting vascular integrity induced by targeted radiation therapy
MX2021008943A (es) 2019-01-25 2021-11-04 Janssen Pharmaceutica Nv Metodos para mitigar la lesion hepatica y promover la hipertrofia hepatica, la regeneracion e injerto celular en conjunto con tratamientos de radiacion y/o radiomimeticos.
EP3914286B1 (en) 2019-01-25 2025-05-07 Janssen Pharmaceutica NV Methods of mitigating toxic effects of vesicants and caustic gas
WO2020154637A1 (en) * 2019-01-25 2020-07-30 Janssen Pharmaceutica Nv Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure
WO2023056444A1 (en) 2021-10-01 2023-04-06 Janssen Pharmaceutica N.V. Methods of increasing progenitor cell production
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5326558A (en) 1989-08-08 1994-07-05 Genetics Institute, Inc. Megakaryocytopoietic factor
IL96477A0 (en) 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
DK167813B1 (da) 1989-12-07 1993-12-20 Carlbiotech Ltd As Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
US5571508A (en) 1989-12-18 1996-11-05 Amrad Corporation Limited Method for the treatment of thrombocytopenia and pharmaceutical compositions useful therefor
IT1241395B (it) 1990-04-02 1994-01-10 Eniricerche Spa Composti immunogenici,il procedimento per la loro sintesi e loro impiego per la preparazione di vaccini antimalaria
US5141851A (en) 1990-04-18 1992-08-25 Board Of Regents, The University Of Texas System Isolated farnesyl protein transferase enzyme
US5250732A (en) 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
AU680422B2 (en) 1992-06-11 1997-07-31 Alkermes Controlled Therapeutics, Inc. Erythropoietin drug delivery system
JP3401005B2 (ja) 1992-12-11 2003-04-28 ユニバーシティ オブ フロリダ 有害生物の防除のための材料および方法
WO1995011922A1 (en) 1993-10-29 1995-05-04 Affymax Technologies N.V. In vitro peptide and antibody display libraries
GB2285446B (en) 1994-01-03 1999-07-28 Genentech Inc Thrombopoietin
WO1995021919A2 (en) 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
EP0723456A1 (en) 1994-02-14 1996-07-31 The University Of Washington Methods for stimulating erythropoiesis using thrombopoietin
EP0668352A1 (en) 1994-02-14 1995-08-23 Kirin Brewery Company, Ltd. Protein having TPO activity
NZ271230A (en) 1994-02-14 1998-03-25 Zymogenetics Inc Hematopoietic proteins, production and use
GEP20002180B (en) 1994-03-31 2000-07-25 Amgen Inc Composition and Methods for Stimulating Megakaryocyte Growth and Differentiation
US5571686A (en) 1994-04-14 1996-11-05 Massachusetts Institute Of Technology Method of using megapoietin for prolonging the survival & viability of platlets
KR100376150B1 (ko) * 1994-11-04 2003-11-01 산텐 세이야꾸 가부시키가이샤 히드록시기를함유하는1,3-디알킬우레아유도체
AU4163196A (en) 1994-11-30 1996-06-19 Zymogenetics Inc. Low molecular weight thrombopoietin
US5641655A (en) 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
JP3763846B2 (ja) 1995-04-26 2006-04-05 協和醗酵工業株式会社 新規ポリペプチド
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US6083913A (en) * 1995-06-07 2000-07-04 Glaxo Wellcome Inc. Peptides and compounds that bind to a thrombopoietin receptor
US6251864B1 (en) * 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
US6060052A (en) 1995-10-30 2000-05-09 Systemix, Inc. Methods for use of Mpl ligands with primitive human hematopoietic stem cells
US5932546A (en) 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
WO2001021180A1 (en) 1999-09-24 2001-03-29 Smithkline Beecham Corporation Thrombopoietin mimetics
CZ299141B6 (cs) * 2000-12-22 2008-04-30 Ipsen Manufacturing Ireland Limited Zpusob syntézy peptidu LHRH
WO2002078612A2 (en) 2001-04-02 2002-10-10 Euro-Celtique S.A. Thrombopoietin (tpo) synthebody for stimulation of platelet production
ES2781475T3 (es) * 2002-09-18 2020-09-02 Janssen Pharmaceuticals Inc Métodos para aumentar la producción de células madre hematopoyéticas y plaquetas
SG131110A1 (en) 2003-08-28 2007-04-26 Ortho Mcneil Pharm Inc Peptides and compounds that bind to thrombopoietin receptors

Similar Documents

Publication Publication Date Title
JP2007504132A5 (enExample)
Ding et al. Weak bond-based injectable and stimuli responsive hydrogels for biomedical applications
JP6309980B2 (ja) 抗バイオフィルム剤を制御放出するためのナノ粒子及びその使用方法
JP6518588B2 (ja) 歯の障害を治療するための組成物の製造方法
EP1713450B1 (en) Rapidly dissolving film for delivery of an active agent
JP2003113113A5 (enExample)
JP2003525912A5 (enExample)
ZA200603950B (en) Pharmaceutical formulations for the sustained release of one or more active principles and applications thereof, such as therapeutic applications
AU2015205438B2 (en) Peptide dendrimers comprising fibrinogen-binding peptides
JP2010505444A5 (enExample)
EP2316490A3 (en) Methods and compositions for enhanced delivery of bioactive molecules
EP2525829A1 (en) Dipeptide-based prodrug linkers for aromatic amine-containing drugs
JP2004504406A5 (enExample)
CA2537421A1 (en) Peptides and compounds that bind to thrombopoietin receptor
RU2007131504A (ru) Пептиды, обладающие агонистической активностью в отношении рецептора нейропептида-2-(y2r)
HUP0104744A2 (hu) Fogsorragasztó
JP2010513327A5 (enExample)
JP2005058499A (ja) 生体材料
WO2023138191A1 (zh) 一种口腔护理组合物及其制备方法和应用
JP2006519782A5 (enExample)
EP1968638B1 (en) Controlled release gels
JP2009504650A5 (enExample)
JP2003504312A5 (enExample)
JP5281358B2 (ja) 高分子、経上皮吸収促進剤、及び医薬用製剤
US20170100484A1 (en) Drug delivery carrier for sustained release of medicinal proteins and method for production thereof